Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 2
2006 2
2007 6
2008 2
2010 3
2011 6
2012 4
2013 5
2014 4
2015 4
2016 7
2017 5
2018 4
2019 9
2020 9
2021 7
2022 12
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
PATZ1 in Non-Small Cell Lung Cancer: A New Biomarker That Negatively Correlates with PD-L1 Expression and Suppresses the Malignant Phenotype.
Lucà S, Franco R, Napolitano A, Soria V, Ronchi A, Zito Marino F, Della Corte CM, Morgillo F, Fiorelli A, Luciano A, Palma G, Arra C, Battista S, Cerchia L, Fedele M. Lucà S, et al. Among authors: morgillo f. Cancers (Basel). 2023 Apr 6;15(7):2190. doi: 10.3390/cancers15072190. Cancers (Basel). 2023. PMID: 37046851 Free PMC article.
Non-small cell lung cancer (NSCLC), the leading cause of cancer death worldwide, is still an unmet medical problem due to the lack of both effective therapies against advanced stages and markers to allow a diagnosis of the disease at early stages before its p …
Non-small cell lung cancer (NSCLC), the leading cause of cancer death worldwide, is still an unmet medical problem due …
Role and targeting of anaplastic lymphoma kinase in cancer.
Della Corte CM, Viscardi G, Di Liello R, Fasano M, Martinelli E, Troiani T, Ciardiello F, Morgillo F. Della Corte CM, et al. Among authors: morgillo f. Mol Cancer. 2018 Feb 19;17(1):30. doi: 10.1186/s12943-018-0776-2. Mol Cancer. 2018. PMID: 29455642 Free PMC article. Review.
Anaplastic lymphoma kinase (ALK) gene activation is involved in the carcinogenesis process of several human cancers such as anaplastic large cell lymphoma, lung cancer, inflammatory myofibroblastic tumors and neuroblastoma, as a consequence of fusion with other onco …
Anaplastic lymphoma kinase (ALK) gene activation is involved in the carcinogenesis process of several human cancers such as anaplastic large …
A Critical Issue in Lung Cancer Cytology and Small Biopsies: DNA and RNA Extraction from Archival Stained Slides for Biomarker Detection through Real Time PCR and NGS-The Experience in Pathological Anatomy Unit.
Zannini G, Tedesco I, Cozzolino I, Montella M, Clery E, Della Corte CM, Morgillo F, Accardo M, Franco R, Zito Marino F. Zannini G, et al. Among authors: morgillo f. Diagnostics (Basel). 2023 May 5;13(9):1637. doi: 10.3390/diagnostics13091637. Diagnostics (Basel). 2023. PMID: 37175028 Free PMC article.
A series of 35 lung adenocarcinoma surgical samples was selected to set up the method and the technical approach was validated in a series of 15 small biopsies and 38 cytological samples. ...Our technical approach based on the recovery of stained slides could represent a s …
A series of 35 lung adenocarcinoma surgical samples was selected to set up the method and the technical approach was validated in a s …
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.
Bria E, Morgillo F, Garassino MC, Ciardiello F, Ardizzoni A, Stefani A, Verderame F, Morabito A, Chella A, Tonini G, Gilli M, Del Signore E, Berardi R, Mencoboni M, Bearz A, Delmonte A, Migliorino MR, Gridelli C, Pazzola A, Iero M, De Marinis F. Bria E, et al. Among authors: morgillo f. Oncologist. 2024 Feb 20:oyad342. doi: 10.1093/oncolo/oyad342. Online ahead of print. Oncologist. 2024. PMID: 38377176 Free article.
BACKGROUND: MAURIS is an Italian multicenter, open-label, phase IIIb ongoing trial, aiming at evaluating the safety and effectiveness of atezolizumab + carboplatin/etoposide in patients with newly diagnosed, extensive-stage small-cell lung cancer (ES-SCLC). The prim …
BACKGROUND: MAURIS is an Italian multicenter, open-label, phase IIIb ongoing trial, aiming at evaluating the safety and effectiveness of ate …
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario.
Cantini L, Mentrasti G, Russo GL, Signorelli D, Pasello G, Rijavec E, Russano M, Antonuzzo L, Rocco D, Giusti R, Adamo V, Genova C, Tuzi A, Morabito A, Gori S, Verde N, Chiari R, Cortellini A, Cognigni V, Pecci F, Indini A, De Toma A, Zattarin E, Oresti S, Pizzutilo EG, Frega S, Erbetta E, Galletti A, Citarella F, Fancelli S, Caliman E, Della Gravara L, Malapelle U, Filetti M, Piras M, Toscano G, Zullo L, De Tursi M, Di Marino P, D'Emilio V, Cona MS, Guida A, Caglio A, Salerno F, Spinelli G, Bennati C, Morgillo F, Russo A, Dellepiane C, Vallini I, Sforza V, Inno A, Rastelli F, Tassi V, Nicolardi L, Pensieri V, Emili R, Roca E, Migliore A, Galassi T, Rocchi MLB, Berardi R. Cantini L, et al. Among authors: morgillo f. ESMO Open. 2022 Apr;7(2):100406. doi: 10.1016/j.esmoop.2022.100406. Epub 2022 Feb 3. ESMO Open. 2022. PMID: 35219245 Free PMC article.
INTRODUCTION: COVID-19 has disrupted the global health care system since March 2020. Lung cancer (LC) patients (pts) represent a vulnerable population highly affected by the pandemic. This multicenter Italian study aimed to evaluate whether the COVID-19 outbreak had …
INTRODUCTION: COVID-19 has disrupted the global health care system since March 2020. Lung cancer (LC) patients (pts) represent …
Therapies in the pipeline for small-cell lung cancer.
Romanidou O, Imbimbo M, Mountzios G, Abidin A, Morgillo F, Califano R. Romanidou O, et al. Among authors: morgillo f. Br Med Bull. 2016 Sep;119(1):37-48. doi: 10.1093/bmb/ldw022. Epub 2016 Jun 20. Br Med Bull. 2016. PMID: 27325208 Review.
INTRODUCTION OR BACKGROUND: Small-cell lung cancer (SCLC) represents ~15% of all cases of lung cancer and is characterized by a rapid tumour doubling time, early onset disease dissemination and high sensitivity to chemotherapy. ...
INTRODUCTION OR BACKGROUND: Small-cell lung cancer (SCLC) represents ~15% of all cases of lung cancer and is cha …
Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications.
Zito Marino F, Bianco R, Accardo M, Ronchi A, Cozzolino I, Morgillo F, Rossi G, Franco R. Zito Marino F, et al. Among authors: morgillo f. Int J Med Sci. 2019 Jun 10;16(7):981-989. doi: 10.7150/ijms.34739. eCollection 2019. Int J Med Sci. 2019. PMID: 31341411 Free PMC article. Review.
In this review, we provide an overview of recognized mechanisms underlying molecular heterogeneity in lung cancer, including epigenetic mechanisms, mutant allele specific imbalance, genomic instability, chromosomal aberrations, tumor mutational burden, somatic mutat …
In this review, we provide an overview of recognized mechanisms underlying molecular heterogeneity in lung cancer, including e …
Metformin in lung cancer: rationale for a combination therapy.
Morgillo F, Sasso FC, Della Corte CM, Festino L, Manzo A, Martinelli E, Troiani T, Capuano A, Ciardiello F. Morgillo F, et al. Expert Opin Investig Drugs. 2013 Nov;22(11):1401-9. doi: 10.1517/13543784.2013.828691. Epub 2013 Aug 12. Expert Opin Investig Drugs. 2013. PMID: 23937224 Review.
INTRODUCTION: Metformin is a widely used antidiabetic drug, which also displays significant growth inhibitory and proapoptotic effects in several cancer models, including lung cancer, alone or in combination with chemotherapeutic drugs. AREAS COVERED: The rol …
INTRODUCTION: Metformin is a widely used antidiabetic drug, which also displays significant growth inhibitory and proapoptotic effects in se …
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers.
Lobefaro R, Viscardi G, Di Liello R, Massa G, Iacovino ML, Sparano F, Della Corte CM, Ferrara R, Signorelli D, Proto C, Prelaj A, Galli G, De Toma A, Brambilla M, Ganzinelli M, Trevisan B, Ciardiello F, De Braud F, Morgillo F, Garassino MC, Lo Russo G. Lobefaro R, et al. Among authors: morgillo f. Lung Cancer. 2021 Feb;152:165-173. doi: 10.1016/j.lungcan.2020.12.027. Epub 2020 Dec 28. Lung Cancer. 2021. PMID: 33421923
BACKGROUND: The introduction of immunotherapy has improved the prognosis of patients with Non-Small Cell Lung Cancer (NSCLC). However, data in poor ECOG Performance Status (PS) patients remain scant due to their exclusion from randomized trials. ...
BACKGROUND: The introduction of immunotherapy has improved the prognosis of patients with Non-Small Cell Lung Cancer (NSCLC). …
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study.
Di Liello R, Ciaramella V, Barra G, Venditti M, Della Corte CM, Papaccio F, Sparano F, Viscardi G, Iacovino ML, Minucci S, Fasano M, Ciardiello F, Morgillo F. Di Liello R, et al. Among authors: morgillo f. ESMO Open. 2019 Aug 19;4(4):e000536. doi: 10.1136/esmoopen-2019-000536. eCollection 2019. ESMO Open. 2019. PMID: 31555484 Free PMC article.
In this work, we present a clinical case of a patient with non-small cell lung cancer (NSCLC) accompanied by a translational study with the intent to assess the correspondence of drug sensitivity in ex vivo spheroidal tumour cultures and peripheral blood biomarkers …
In this work, we present a clinical case of a patient with non-small cell lung cancer (NSCLC) accompanied by a translational s …
91 results